Selecta Biosciences - SELB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.33
  • Forecasted Upside: 316.67 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.28
▼ -0.03 (-2.29%)

This chart shows the closing price for SELB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Selecta Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SELB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SELB

Analyst Price Target is $5.33
▲ +316.67% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Selecta Biosciences in the last 3 months. The average price target is $5.33, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a 316.67% upside from the last price of $1.28.

This chart shows the closing price for SELB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Selecta Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2022HC WainwrightLower TargetBuy$6.00 ➝ $4.00Low
6/14/2022Needham & Company LLCLower TargetBuy$6.00 ➝ $5.00High
6/6/2022SVB LeerinkInitiated CoverageOutperform$7.00High
1/11/2022HC WainwrightReiterated RatingBuy$6.00Low
12/2/2021HC WainwrightReiterated RatingBuy$6.00High
11/15/2021HC WainwrightReiterated RatingBuy$6.00Low
11/1/2021Needham & Company LLCBoost TargetBuy$6.00 ➝ $7.00Medium
10/22/2021HC WainwrightReiterated RatingBuy$6.00Low
10/11/2021Needham & Company LLCReiterated RatingBuy$6.00Low
10/5/2021HC WainwrightReiterated RatingBuy$6.00High
9/9/2021HC WainwrightReiterated RatingBuy$6.00Low
9/2/2021HC WainwrightReiterated RatingBuy$6.00High
7/27/2021Berenberg BankReiterated RatingBuy$3.50Medium
7/27/2021HC WainwrightReiterated RatingBuy$6.00Medium
6/14/2021BTIG ResearchInitiated CoverageBuy$10.00High
5/3/2021HC WainwrightReiterated RatingBuyLow
3/12/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
1/26/2021MizuhoUpgradeNeutral ➝ Buy$2.50 ➝ $8.00High
1/7/2021HC WainwrightReiterated RatingBuy$6.00N/A
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
10/5/2020HC WainwrightLower TargetBuy$10.00 ➝ $6.00Low
10/1/2020MizuhoDowngradeBuy ➝ Neutral$7.00 ➝ $2.50High
10/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
8/7/2020MizuhoReiterated RatingBuy$7.00Medium
6/18/2020HC WainwrightReiterated RatingBuy$10.00High
6/18/2020Stifel NicolausReiterated RatingHoldHigh
6/18/2020Needham & Company LLCReiterated RatingBuy$5.00Medium
6/12/2020Needham & Company LLCReiterated RatingBuy$5.00High
6/12/2020Stifel NicolausDowngradeBuy ➝ Hold$4.00High
6/12/2020HC WainwrightBoost TargetBuy$8.00 ➝ $10.00High
6/10/2020MizuhoReiterated RatingBuy$7.00Low
5/7/2020Stifel NicolausReiterated RatingBuy$4.00High
5/7/2020Needham & Company LLCReiterated RatingBuy$5.00High
5/7/2020William BlairReiterated RatingBuyHigh
4/28/2020HC WainwrightInitiated CoverageBuy$8.00High
3/12/2020Stifel NicolausReiterated RatingBuy$4.00High
2/18/2020MizuhoReiterated RatingBuy$4.00 ➝ $7.00High
1/29/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00Low
1/21/2020William BlairInitiated CoverageOutperformHigh
12/19/2019MizuhoReiterated RatingBuy$4.00Low
12/19/2019Stifel NicolausReiterated RatingBuyHigh
11/8/2019Needham & Company LLCReiterated RatingBuy$9.00Low
11/8/2019Stifel NicolausReiterated RatingBuy$6.00Low
8/11/2019MizuhoReiterated RatingBuy$4.00Medium
8/9/2019Stifel NicolausReiterated RatingBuy$6.00Low
5/10/2019MizuhoReiterated RatingBuy$4.00Low
3/15/2019Stifel NicolausReiterated RatingBuy$7.00Medium
2/5/2019Stifel NicolausSet TargetBuy$7.00Medium
2/4/2019MizuhoLower TargetBuy$4.00Low
1/28/2019Needham & Company LLCLower TargetBuy$12.00Low
11/9/2018UBS GroupSet TargetHold$6.00Medium
11/5/2018MizuhoReiterated RatingBuy$30.00Medium
10/23/2018Janney Montgomery ScottReiterated RatingBuyHigh
10/23/2018Stifel NicolausReiterated RatingBuyMedium
10/17/2018MizuhoReiterated RatingBuy$30.00High
9/14/2018Stifel NicolausInitiated CoverageBuy$24.00Low
8/9/2018MizuhoReiterated RatingBuy$30.00High
6/27/2018Janney Montgomery ScottInitiated CoverageBuy$33.00Low
4/11/2018MizuhoReiterated RatingBuy$30.00High
2/26/2018MizuhoInitiated CoverageBuy$30.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/10/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/10/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/9/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/8/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/7/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Selecta Biosciences logo
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $1.28
Low: $1.26
High: $1.31

50 Day Range

MA: $1.52
Low: $1.24
High: $1.75

52 Week Range

Now: $1.28
Low: $0.65
High: $3.64

Volume

13,390 shs

Average Volume

637,686 shs

Market Capitalization

$195.88 million

P/E Ratio

10.67

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Selecta Biosciences?

The following Wall Street analysts have issued reports on Selecta Biosciences in the last year: HC Wainwright, Needham & Company LLC, StockNews.com, SVB Leerink LLC, and TheStreet.
View the latest analyst ratings for SELB.

What is the current price target for Selecta Biosciences?

3 Wall Street analysts have set twelve-month price targets for Selecta Biosciences in the last year. Their average twelve-month price target is $5.33, suggesting a possible upside of 316.7%. SVB Leerink LLC has the highest price target set, predicting SELB will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $4.00 for Selecta Biosciences in the next year.
View the latest price targets for SELB.

What is the current consensus analyst rating for Selecta Biosciences?

Selecta Biosciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SELB will outperform the market and that investors should add to their positions of Selecta Biosciences.
View the latest ratings for SELB.

What other companies compete with Selecta Biosciences?

How do I contact Selecta Biosciences' investor relations team?

Selecta Biosciences' physical mailing address is 65 Grove Street, Watertown MA, 02472. The company's listed phone number is (617) 923-1400 and its investor relations email address is [email protected] The official website for Selecta Biosciences is selectabio.com. Learn More about contacing Selecta Biosciences investor relations.